Telerehabilitation for Multiple Sclerosis

Not Applicable

Completed

• Conditions: Multiple Sclerosis

• Registration Number: NCT06871072
• Lead Sponsor: University of Cadiz

Brief Summary

Multiple sclerosis (MS) is a neurodegenerative disease affecting the central nervous system and is a leading cause of disability in young adults. It often produces strength deficits. Exercise has been shown to improve strength, mobility, and quality of life while reducing fatigue. Telerehabilitation offers a convenient, accessible alternative for MS patients. This study explores the use of an AI-powered application for prescribing and monitoring strength exercises, ensuring continuous feedback and adherence. Methods: Randomized clinical trial. Intervention of 3 weekly strength training ses-sions for 20 weeks, patients in the experimental group used the AI application, while patients in the control group followed the conventional method, paper-based exercises with access to videos.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-04
• Primary Completion: 2024-11-10
• Study Completion: 2024-12-25
• Study First Submitted: 2025-02-27
• Status Verified: 2025-03
• Study First Submitted QC: 2025-03-06
• Last Update Submitted: 2025-03-06
• Study First Posted: 2025-03-11
• Last Update Posted: 2025-03-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

• Diagnosis of multiple sclerosis according to the McDonald criteria 2017:
• Age between 35 and 60 years.
• Score on the Expanded Disability Status Scale in Multiple Sclerosis by Kurtzke (EDSS) between 2 and 6 points.
• Patients who do not require assistive devices for home mobility.
• Patients with no changes in disease-modifying treatment in the last 3 months.
• Patients who have understood, completed, and signed the informed consent and the study information sheet.

Exclusion Criteria

• Patients who have been regularly performing strength exercises for more than 3 months prior.
• Moderate/severe cognitive impairment that may interfere with the understanding and/or execution of the study.
• History of alcohol and/or drug abuse.
• Presence of a relapse and/or treatment with corticosteroids within the four weeks prior to the start of the study.
• Patients with severe comorbidities other than MS that may pose a risk for following the exercise guidelines or for their participation in the study for other reasons.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Maximal Strength	Baseline	Maxi-mal Strength was assessed using an 8-repetition maximum test , in which par-ticipants perform 8 repetitions of squat and bench press as the resistance is gradually increased until a load is determined where only eight repetitions can be performed. The load increment was determined based on the result from the Modified Borg Scale at the end of the exercise, if the Borg rating was greater than 7, the test was completed.

Secondary Outcome Measures

Name	Time	Method
Maximal Strength.	Twenty weeks.	Maxi-mal Strength was assessed using an 8-repetition maximum test, in which par-ticipants perform 8 repetitions of squat and bench press as the resistance is gradually increased until a load is determined where only eight repetitions can be performed. The load increment was determined based on the result from the Modified Borg Scale at the end of the exercise, if the Borg rating was greater than 7, the test was completed.
Strength endurance.	twenty weeks.	Strength endurance was measured by the maximum number of unilateral knee flexion-extension repetitions performed in 30 seconds
Endurance capacity.	Twenty weeks	Endurance capacity as secondary variable was measured by 6-minutes walking test, where participants covering the maximum distance on a flat surface in 6 minutes. Fatigue was quantified by Modified Fatigue Impact Scale

Trial Locations

Locations (1)

Macarena University Hospital; 🇪🇸 Sevilla, Spain